Patent Term Extension for Innovative Drugs in China: A Cohort Study from 2021 to 2024
Compared to findings from prior studies on the U.S. and the European Union, the median PTE duration for innovative drugs in China is longer, while the median EPLL is only marginally extended. Both Chinese domestic stakeholders and foreign enterprises should evaluate the potential impact by considering both the incremental PTE periods and the overall EPLL levels.
Authors
- Jin Zhou (ORCID: https://orcid.org/0000-0002-6829-6149)
- Xiangdong Yao (ORCID: https://orcid.org/0000-0002-1235-5090)
- Yan Zhang (ORCID: https://orcid.org/0000-0001-7039-9780)
Institutions
- Nanjing University of Chinese Medicine (CN)
Publication Details
- Journal
- Therapeutic Innovation & Regulatory Science
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1007/s43441-025-00903-x
- Primary Topic
- Intellectual Property and Patents
- Type
- article
- Field-Weighted Citation Impact
- 0.00